Study of the Effect of Memantine on Negative Sign in Patients with Schizophrenia and Schizoaffective Disorders

Memantine, an uncompetitive antagonist of glutamate receptor of the N-methyl-D-aspartate type is approved for the treatment of moderate to severe Alzheimer disease (1). A growing body of evidence supports a link between the glutamatergic neurotransmission and schizophrenia (2). The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavakoli-Ardakani, Maria, Abbaspour, Hamide, Farhadi Nasab, Abdollah, Mazaheri Meibodi, Azadeh, Kheradmand, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958331/
https://www.ncbi.nlm.nih.gov/pubmed/29796036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5958331/
https://www.ncbi.nlm.nih.gov/pubmed/29796036

Ejemplares similares